Beijing Science Sun Pharmaceutical Co., Ltd.

The company's major business is R & D, production and sales of injections, involving three major fields of natural or biotechnology drugs such as cardiovascular and cerebrovascular diseases, immune diseases (anti-tumor) and the nervous system. The Company’s main products of such as Fibrinogenase Injection, Bozhi Glycopeptide Injcetion, Sodium Deoxyribonucleotide Injection, 100mg Thymopolypeptides for Injection are the first or the exclusive large varieties of production in China. Moreover, Monosialotetrahexosylganglioside sodium Injection and Bozhi Glycopeptide Injcetion are national key new products. With respect to production, the company and its holding subsidiary, Sai Er BIO, have small volume of injection, lyophilized powder injection (including hormones), tablets (including cephalosporins), capsules (including cephalosporins), powders, granules, BPC and other multi-dose production licenses. The company has completed upstream and downstream product industrial chain, is able to simultaneously be engaged in R & D, production and sales of BPC, oral drugs, and injection. The company has a complete production quality management system, including two workshops which have passed the 2010 GMP certification of sterile drug production, four production lines of small volume injection and lyophilized powder injection. In respect of research and development, while continuing to increase R & D investment and strengthening management, the Company has not only conducted in-depth studies on process optimization of its core products, but also improved its existing product quality and stabilized market demand. On the other hand, the company has actively promoted R&D for new product, by doing so, the company is striving to enrich the product variety and improve the technical competitiveness. In addition to the sustained investment with respect to the R&D of new varieties of cardio-cerebral vascular system medication, anti-tumor and immunomodulator drugs, and neurological drugs; the company will also strengthen the development of new drug delivery technology, increase R & D investment to peptide, and new products of biotechnology, and constantly improve the company’s product structure. In terms of marketing, the company's marketing network system covers major cities in the country and has established a marketing network that covers the whole country in the form of investment promotion by resident managers from other regions. The company has more than thousands of long-term, stable cooperative dealers, and the products distributed widely in the region. The company has established perfect and smooth product sales channels, and shown strong potential for development. In 2016, as the main sponsor, the company united Beijing E-town International Investment & Development Co.,Ltd and Beijing Yizhuang Biomedical Park to establish the Beijing E-town Biomedical M&A Fund. The fund was approved as the only biomedical fund among the first batch of cooperation partners of the sophisticated FOF established by Beijing Municipal Commission of Economy and Information Technology. In 2017, by a successful auction of 45 percent equity of Beijing Protein Innovation, the future expansion of the company’s investment will be scaled up exponentially as expected. In 2018, the company participated the establishment and operation of Suzhou Danqing II Innovative Healthcare Investment L.P. and the acquisition of Shenyang Dongan Pharmaceutical Inc., which name was changed to Shenyang Junyuan Pharmaceutical Inc. after the aquisition.In 2019,the company acquired Beijing Lvzhu Biotechnology Co., Ltd. and Zhejiang SaiLingTe Pharmaceutical Technology Co., Ltd. The Company and its subsidiaries have obtained 210 pharmaceutical approval documents, 3 national new drug product certificates, 2 national key new product certificates，and the drafting unit for a number of national standards of medicines. The company is one of the national standard drafting companies for many drugs.